Ironwood Pharma (IRWD) AI Stock Analysis

• Market Cap: $269.64M
• Dividend Yield: N/A
• Average Volume (3M): 1.22M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: -22.98%
• EPS Growth: -173.28%
• Country: US
• Employees: 253
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.14
• Shares Outstanding: 162,434,130
• 10 Day Avg. Volume: 883,204
• 30 Day Avg. Volume: 1,218,100
• PEG Ratio: -8.00
• Price to Book (P/B): -2.34
• Price to Sales (P/S): 2.01
• P/FCF Ratio: 6.82
• Enterprise Value/Market Cap: 2.35
• Enterprise Value/Revenue: 2.05
• Enterprise Value/Gross Profit: 2.28
• Enterprise Value/Ebitda: 7.91
• 1Y Price Target: $1.00
• Price Target Upside: -39.76% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 50 Neutral
• Price Target: $1.50 ▼(-9.64% Downside)

Ironwood Pharma's overall stock score is primarily impacted by its financial instability, characterized by negative equity and high leverage. While technical indicators suggest moderate positive momentum, the valuation remains unattractive due to a negative P/E ratio. The absence of earnings call insights and corporate events limits additional context.

Positive Factors

Product Portfolio

Ironwood's focus on GI diseases with a flagship product like Linzess provides a strong niche market position, leveraging specialized expertise to drive patient outcomes and revenue.

Strategic Collaborations

Collaborations expand Ironwood's market reach and product development, potentially increasing revenue through shared developments and co-promotion agreements.

Cash Generation Ability

Positive operating cash flow and efficient cash generation relative to net income indicate strong cash management, supporting operational stability.

Negative Factors

Revenue Decline

A declining revenue growth rate indicates challenges in maintaining market share or product demand, potentially impacting long-term financial health.

High Leverage

High leverage and negative equity suggest financial instability, which could constrain future growth and investment opportunities.

Profitability Challenges

Negative profitability and declining margins highlight operational inefficiencies, requiring strategic adjustments to enhance financial performance.

Ironwood Pharma Business Overview & Revenue Model

Company Description

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Ironwood generates revenue primarily through the sales of its commercialized products, with Linzess being the most significant contributor to its earnings. The company operates on a revenue model that includes direct product sales, as well as potential royalties and milestone payments from partnerships and collaborations with other pharmaceutical companies. Ironwood has established strategic collaborations to enhance its product pipeline and expand market reach, which can further augment its revenue through shared developments and co-promotion agreements. Additionally, the company may benefit from reimbursement agreements with healthcare providers and payers, which facilitate patient access to its therapies and support revenue growth.

Ironwood Pharma Financial Statement Overview

Summary

Ironwood Pharma faces financial challenges with declining revenues, negative profitability, and high leverage. Despite a strong gross profit margin and positive operating cash flow, the negative equity and substantial debt levels are concerning.

Income Statement

Ironwood Pharma's income statement shows a mixed performance. The TTM data reveals a negative net profit margin, indicating losses, and a declining revenue growth rate of -2.88%. The gross profit margin remains strong at 90%, but the EBIT and EBITDA margins have decreased compared to previous years. The company needs to address its declining revenues and profitability to improve its financial health.

Balance Sheet

The balance sheet presents significant challenges, with a negative stockholders' equity and a high debt-to-equity ratio of -1.94 in the TTM period. This indicates financial instability and potential solvency issues. The return on equity is slightly positive in the TTM, but the negative equity and high leverage pose substantial risks to the company's financial stability.

Cash Flow

The cash flow statement shows a significant decline in free cash flow growth at -61.82% in the TTM period. However, the operating cash flow remains positive, and the free cash flow to net income ratio is nearly 1, suggesting efficient cash generation relative to net income. Despite the decline in free cash flow growth, the company maintains a reasonable cash flow position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	308.52M	351.41M	442.74M	410.60M	413.75M	389.52M
Gross Profit	277.75M	343.86M	442.74M	409.18M	412.23M	298.32M
EBITDA	80.02M	100.24M	-924.87M	261.44M	233.33M	141.90M
Net Income	-7.88M	880.00K	-1.00B	175.06M	528.45M	106.18M
Balance Sheet
Total Assets	342.95M	350.91M	471.07M	1.10B	1.13B	559.24M
Cash, Cash Equivalents and Short-Term Investments	92.85M	88.56M	92.15M	656.20M	620.13M	362.56M
Total Debt	598.67M	599.48M	715.54M	415.92M	475.80M	453.70M
Total Liabilities	651.11M	652.24M	817.37M	448.14M	521.02M	496.60M
Stockholders Equity	-308.16M	-301.33M	-346.30M	652.38M	605.91M	62.64M
Cash Flow
Free Cash Flow	29.94M	103.41M	183.15M	273.63M	261.63M	166.99M
Operating Cash Flow	29.98M	103.55M	183.43M	273.76M	261.89M	168.84M
Investing Cash Flow	-65.00K	-142.00K	-1.03B	-136.00K	-265.00K	-1.84M
Financing Cash Flow	-41.95M	-106.97M	277.16M	-237.55M	-4.55M	18.55M

Ironwood Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRWD, the sentiment is Positive. The current price of 1.66 is above the 20-day moving average (MA) of 1.54, above the 50-day MA of 1.37, and above the 200-day MA of 1.34, indicating a bullish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 59.24 is Neutral, neither overbought nor oversold. The STOCH value of 62.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRWD.

Ironwood Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COLL	―	$1.11B	34.08	16.16%	―	22.61%	-63.00%
ANIP	―	$2.04B	―	-2.82%	―	38.68%	-160.14%
DVAX	―	$1.22B	―	-9.28%	―	26.66%	-419.55%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PCRX	―	$976.84M	―	-15.57%	―	2.25%	-301.59%
IRWD	―	$269.64M	―	―	―	-22.98%	-173.28%
EVO	―	$1.44B	―	-16.34%	―	-1.03%	8.13%

Ironwood Pharma Corporate Events

Ironwood Pharma Board Member Resigns for New Role

On October 7, 2025, Andrew Dreyfus announced his resignation from the Board of Directors of Ironwood Pharmaceuticals, Inc., effective November 1, 2025. His departure is due to his new role as President and CEO of the National Institute for Health Care Management Foundation and is not related to any disagreements with Ironwood Pharmaceuticals. The company expressed gratitude for his contributions during his tenure.

The most recent analyst rating on (IRWD) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.

Ironwood Pharma Regains Nasdaq Compliance

On August 29, 2025, Ironwood Pharmaceuticals announced it has regained compliance with Nasdaq’s minimum bid price requirement, following a previous notice of non-compliance on May 28, 2025. This compliance ensures the company’s continued inclusion on the Nasdaq Global Select Market, marking a positive development for its market positioning.

The most recent analyst rating on (IRWD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.

Ironwood Pharmaceuticals Reports Strong Q2 2025 Results

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for gastrointestinal and rare diseases, with a notable product, LINZESS, for treating irritable bowel syndrome with constipation and chronic idiopathic constipation.